secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001933414-25-000139
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys Therapeutics Q3 net loss $36.9M; NDA planned late-2025/Q1 2026; cash $593.6M
--------------------------------------------------------------------------------

- Net loss $36.9M for Q3 2025 vs $56.3M YoY; R&D expenses fell to $31.5M from $54.0M.
- Cash, cash equivalents and investments $593.6M at Sep 30, 2025 (Dec 31, 2024: $198.2M) after $287.5M equity financing.
- NDA submission for lorundrostat planned late 2025 or Q1 2026 following pre-NDA FDA feedback.
- Enrollment complete in Explore-OSA Phase 2 trial; topline data anticipated Q1 2026.
- Company expects current cash to fund planned clinical and regulatory activities into 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341425000139/0001933414-25-000139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341425000139/mlys-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001933414-25-000139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer